Thrombate III

 Advanced Search
United States
United States | For US Healthcare Professionals Only
Print This Page

Hypermunes™ Hyperimmune Globulin Therapy

Hyperimmune globulin therapy is concentrated immunoglobulins used to treat patients whose immune systems have been compromised. Constant monitoring in steps of the manufacturing and delivery process make these biological products safe, easy, and convenient to use. A doctor or healthcare provider prescribes hyperimmune globulin therapies.

Please note: Country-specific regulatory requirements limit the information we can provide about our products. In addition, approved indications (uses), product labels, and packaging for a prescription drug may differ between countries. Please refer to the prescribing information provided for your country of residence.

Hypermunes™ Hyperimmune Globulin Therapy reaches patients around the world, including in:

USA

Residents of other countries can learn about Talecris' immunology products on the Talecris International Web site

Or, find local distributors by selecting your region on the location map.


Important Safety Information
Thrombate III therapy has demonstrated a low occurrence of side effects. In clinical studies with Thrombate III, the most common side effects were dizziness, chest tightness, nausea, and a foul taste in the mouth. As with all plasma-derived therapeutics, the potential to transmit infectious agents, such as viruses, cannot be totally eliminated. Individuals who receive infusions of blood or blood plasma may develop signs and/or symptoms of some viral infections, particularly hepatitis C.

Please see full Prescribing Information for Thrombate III.

Thrombate III Home  |   About Thrombate III  |   About Hereditary AT Deficiency  |   How to Order Thrombate III
Online Resources  |   Prescribing Information  |   Site Map  |   Glossary



 
  Talecris Biotherapeutics   Contact Talecris     General Conditions of Use     Privacy Statement    
 
This site is intended for US healthcare professionals only.
© 2007 Talecris Biotherapeutics, Inc.